Patricia Kropf on Home Administration of Synribo for CML

Article

Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).

Patricia Kropf, MD, assistant professor, Division of Bone Marrow Transplants, Fox Chase Cancer Center, discusses home administration of Synribo (omacetaxine mepesuccinate).

In May 2014, the FDA approved home administration of the subcutaneous injection for patients with chronic myelogenous leukemia (CML) who are resistant or intolerant to treatment with tyrosine-kinase inhibitors (TKIs).

Prior to the approval, patients had to travel to the clinic to receive their injections, which Kropf says was burdensome and inconvenient. The injections can be administered by the patients or caregivers.

Kropf adds that she anticipates seeing an expansion of Synribo prescriptions because of the approval.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
© 2024 MJH Life Sciences

All rights reserved.